Bristol Myers and 2seventy bio say FDA delayed CAR-T therapy decision

The FDA is delaying its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy for multiple myeloma in earlier lines of treatment, and it plans to hold a public meeting with outside experts to discuss.

The regulator was originally expected to make a decision by…
Click here to view original post

Advertise With Biotech Networks